SEARCH

SEARCH BY CITATION

References

  • 1
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601606.
  • 2
    Bonvalet JP, Alfaidy N, Farman N, Lombes M. Aldosterone: Intracellular receptors in human heart. Eur Heart J 1995;16(Suppl N):9297.
  • 3
    Capen CC. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol 1997;25:3948.
  • 4
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303310.
  • 5
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:14291435.
  • 6
    Cook CS, Zhang L, Fischer JS. Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. Pharm Res 2000;17:14261431.
  • 7
    Curran PG, DeGroot LJ. The effect of hepatic enzyme inducing drugs on thyroid hormones and the thyroid gland. EndocrinolRev 1991;12:135150.
  • 8
    Dahlof B. The importance of the renin-angiotensin system in the reversal of left ventricular hypertrophy. J Hypertens 1993;11(Suppl 5):S29S35.
  • 9
    De Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spironolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650656.
  • 10
    Delyani JA. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int 2000;57:14081411.
  • 11
    Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosterone antagonist [abstract]. Am J Hypertens 1998;11:94A.
  • 12
    Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction: Effect on infarct healing and left ventricular remodeling. Am J Physiol Heart Circ Physiol 2001;281:H647H654.
  • 13
    Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215221.
  • 14
    Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993;71:17A20A.
  • 15
    Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:13711376.
  • 16
    Easton WC, Haseman JK, Mahler JF, Bucher JR. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol Pathol 1998;26:461473.
  • 17
    Epstein M, Menard J, Alexander J, Roniker B. Eplerenone, a novel and selective aldosterone receptor antagonist: Efficacy in patients with mild to moderate hypertension [abstract]. Circulation 1998;98:I-98I-99.
  • 18
    Epstein M, Alexander JC, Roniker B. Eplerenone, a new selective aldosterone receptor antagonist (SARA): Efficacy in patients with mild to moderate hypertension [abstract]. J Am Soc Nephrol 1998;9:322A323A.
  • 19
    Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension [abstract]. Hypertension 1999;33:1075.
  • 20
    Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:14501456.
  • 21
    Gómez-Sánchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am JPhysiol 1990;258:E649E653.
  • 22
    Gómez-Sánchez EP, Fort CM, Gómez-Sánchez CE. Intracerebroventricular infusion of RU 28318 blocks aldosterone-salt hypertension. Am J Physiol 1990;258:E482E484.
  • 23
    Hill RN, Crisp TM, Hurley PM, Rosenthal SL, Singh DV. Risk assessment of thyroid follicular cell tumors. Env Health Persp 1998;106:447457.
  • 24
    Karri H, Monika S, Simone M, Ursula S, Thomas U. The role of angiotensin receptors in cardiovascular diseases. Ann Med 1997;29:2329.
  • 25
    Katayama S, Abe M, Ishii J. Differential effects of angiotensin II and aldosterone on cardiovascular hypertrophy. Hypertens Res 1994;17:233237.
  • 26
    Kornel L, Ramsay C, Kanamarlapudi N, Travers T, Packer W. Evidence for the presence in the arterial walls of intracellular-molecular mechanism for action of mineralocorticoids. Clin Exp Hypertens A 1982;4:15611582.
  • 27
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:14561462.
  • 28
    Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet J-P. Prerequisite for cardiac aldosterone action: Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175182.
  • 29
    McClain RM. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol 1989;17:294306.
  • 30
    McElvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;10:10561064.
  • 31
    Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 1998;12:295299.
  • 32
    Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797810.
  • 33
    Pfeffer MA, Brauwald E, Moye LA, et al., for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after mycoardial infarction: Results of the Survival and Ventricular Enlargement Trials. N Engl J Med 1992;327:669677.
  • 34
    Pitt B, Segal R, Martinez FA, et al., for the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747752.
  • 35
    Pitt B, Roniker B, for the Eplerenone Heart Failure Investigators. Eplerenone, a novel selective aldosterone antagonist (SARA):dose finding study in patients with heart failure [abstract]. J Am Coll Cardiol 1999;33:188A189A.
  • 36
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709717.
  • 37
    Rabasseda X, Silvestre J, Castaner J. Eplerenone. Drugs Future 1999;24:488501.
  • 38
    Rocha R, Chander P, Zuckerman A, Mullen D, Bashin K, Stier CT Jr. Aldosterone reverses the protective effects of adrenalectomy against end-organ damage in stroke-prone spontaneously hypertensive rats [abstract]. Am J Hypertens 1999;12:76A.
  • 39
    Rocha R, Stier CT Jr, Adler GK, Ochoa-Maya MR, Kifor I, Williams GH. Aldosterone antagonism and adrenalectomy prevent myocardial necrosis in hypertensive rats [abstract]. Presented at the 81st meeting of the Endocrine Society; June 1215, 1999; San Diego , California .
  • 40
    Rocha R, Stier CT Jr, Rennke H, et al. Aldosterone and cardiovascular injury in L-NAME/Ang II hypertensive rats [asbtract]. Presented at the 53rd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure. September 1316, 1999; Orlando , Florida .
  • 41
    Rocha R, Stier CT Jr, Adler GK, Kifor I, Mullen D, Williams GH. Selective aldosterone antagonist or adrenalectomy prevents L-NAME/A II-induced renal injury in rats [abstract]. Am J Hypertens 1999;12:A15.
  • 42
    Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451458.
  • 43
    Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232237.
  • 44
    Rocha R, Chander PN, Zuckerman A, Stier CT. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats [abstract]. Hypertension 1998;32:598.
  • 45
    Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:38713878.
  • 46
    Roland BL, Krozowski ZS, Funder JW. Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: In situ studies. Mol Cell Endocrinol 1995;111:R1R7.
  • 47
    Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998;273:48834891.
  • 48
    Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138147.
  • 49
    Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: Role of local factors and circulating hormones. Ann Med 1998;30(Suppl 1):38.
  • 50
    Takeda Y, Miyamori I, Inaba S, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29:4548.
  • 51
    Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M, Maeda N. Glucocorticoid- and mineralocorticoid receptors in microglial cells: The two receptors mediate differential effects of corticosteroids. Glia 1997;20:2337.
  • 52
    Tennent RW, French JE, Spalding JW. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Env Health Persp 1995;103:942950.
  • 53
    Tolbert B, Karim A, Cook C, Lonien M, Wermer J. SC-66110 (eplerenone): A selective antialdosterone antagonist: Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. Presented at the American Association of Pharmaceutical Scientists, 1998.
  • 54
    Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:18491865.
  • 55
    Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis and the concepts of cardioprotection and cardioreparation. J Hypertens 1992;10:S87S94.
  • 56
    Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:15171525.
  • 57
    Young M, Head G, Funder JW. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657E662.